此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

无创射频治疗难治性 MGD 的疗效和安全性

2026年11月5日 更新者:The University of Hong Kong

非侵入性射频治疗难治性睑板腺功能障碍患者的疗效和安全性:随机对照试验

The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease.

Participants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.

研究概览

详细说明

Dry eye disease(DED) is a prevalent age-related ophthalmic condition. Depending on the population studied and the diagnostic criteria used, dry eye disease is estimated to have a high prevalence in most populations , with a female preponderance. In the latest 2017 Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) Epidemiology Report, which compiled dry eye prevalence data from studies worldwide, the reported the prevalence of DED ranged from 5 to 50%. The risk of dry eye disease increases with age, where with every increase in 10 years of age, the self-reported symptoms of DED increased by 2%. In one study in Asia, up to 70% of elderly patients greater than 60 years of age suffering from symptomatic dry eye disease. Dry eye disease causes gritty and painful eyes, with associated blurred vision. For sufferers, it poses a significant burden on quality of life and limitations activities on activities of daily living, resulting in considerable economic costs to society. A 2006 health-economics study in the United Kingdom estimated that the annual healthcare costs to the public sector for every 1000 dry eye patients was USD 1.1 million.

The causes of dry eye can be broadly classified into those with aqueous tear deficiency, excessive tear evaporation or a combination of both. The most common cause of excessive tear evaporation is meibomian gland dysfunction (MGD). This is a common condition of the eyelids where there is a significant change in both the consistency and quantity of meibum, resulting in chronic inflammation of the eyelids and subsequent ocular surface dysfunction. MGD has a prevalence from 46.2% to 69.3% in several studies targeting Asian populations, with a trend of higher prevalence in the elderly. Insufficient lipid secretion from meibomian gland undermines tear film stability, producing dry eye symptoms despite normal tear secretion. In a recent study, up to 70.3% of dry eye patients were found to have concurrent MGD. Refractory MGD is defined by the failure to respond to more than at least three types of conventional therapy, including lubricating eyedrops, gels and ointments and topical or systemic anti-inflammatory treatment, in the past two years.

Currently heat-based therapies are the mainstay and most effective strategies against MGD. Eyelid warming, thermal pulsation and intense light therapy are three prevailing heat-based treatments for MGD- related dry eye disease. Eyelid warming usually involves the application of warm towels, commercialized eye masks (EyeGiene® or Blephasteam®) or eye bags (MGDRx Eye Bag) at least twice a day. Thermal pulsation (Lipiflow®) refers to the delivery of controlled heat together with gentle massage to the eyelids by the machine for 10-17 minutes. Intense pulsed light (IPL) therapy, which uses light energy on the skin surface, is widely used in dermatology to treat a variety of conditions including dermal vascular lesions, such as port wine stains and hemangiomas, facial rosacea, and acne. Each treatment strategy however carries significant limitations. Self-applied eyelid warm compress is cheap and easily available, but when used alone has limited efficacy. Furthermore, sustained patient adherence to treatment is difficult long term. A single treatment of thermal pulsation therapy has been shown to have sustained therapeutic effects up to 12 months after treatment. However, thermal pulsation is not effective in moderate to severe cases of MGD. From existing studies, IPL has greater clinical efficacy than thermal pulsation, but its therapeutic effects are maintained for a significantly shorter period. As such, monthly repeated treatments for up to 8 months may be required for sustained effects. It is also important to note that none of the existing treatments allow the eyelids to evacuate inspissated meibum effectively, with meibum expression by an ophthalmologist an important step in the treatment process. Thus, MGD is likely to recur long-term.

The Thermage FLX System (WA, USA) is a non-ablative radiofrequency (RF) energy-based device, which has been widely adopted in the cosmetic industry for radiofrequency tissue tightening. RF transfers high energy fluences through the skin to deep dermal layers uniformly while protecting the epidermis. It is postulated that RF stimulates subdermal collagen production for tissue tightening effect. There are several advantages of using non-invasive RF treatment over other currently available energy-based devices. Firstly, the Thermage FLX has a much more precise applicator directly targeting the meibomian glands. Thermage FLX addresses both the upper and lower eyelids as close as possible to the lid margin, which is directly where the meibomian glands are situated, it also addresses the tragus area as well, hence a more precise and direct treatment area can be achieved. Secondly, compared to other energy-based devices, Thermage FLX provides a higher accumulative heat transfer effect around the periocular region, due to its repeated application of at least 4-5 cycles around the periorbital region. With higher accumulative heat energy, we anticipate a better and more effective melting of the meibum, which aids in more effective meibum expression. Thirdly, as Thermage FLX has been widely adopted for radiofrequency tissue tightening due to its collagen resynthesis effect, there has been proven improvement of the elasticity of orbicularis and periocular skin tissue, this can promote better blinking effort and better apposition of lid margins. This may enhance the pumping effect of the orbicularis oculi in the long-term. RF treatment is potentially a safe and effective multimodal treatment for MGD-related dry eye disease.

研究类型

介入性

注册 (估计的)

112

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Kendrick Co SHIH
  • 电话号码:94326271
  • 邮箱:kcshih@hku.hk

学习地点

      • Hong Kong、香港
        • 招聘中
        • HKU Eye Centre
        • 接触:
          • Kendrick Co SHIH
          • 电话号码:94326271
          • 邮箱:kcshih@hku.hk
    • Hong Kong
      • Hong Kong、Hong Kong、香港
        • 招聘中
        • Grantham Hospital
        • 接触:
          • Kendrick Co Shih

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age 18 or more
  2. Bilateral dry eye disease as confirmed by presence of both symptoms and signs 2.1 Symptoms: Abnormal result on the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) dry eye symptom questionnaire (≥5) 2.2 Signs: Abnormal result in at least one of the following three clinical tests - tear osmolarity, NIKBUT and corneal staining for punctate epithelial erosions and,
  3. Bilateral moderate to severe meibomian gland dysfunction - at least Grade 1 meibum quality (cloudy appearance) and Grade 2 meibum expressibility (moderate pressure required). And,
  4. Refractory MGD - The failure to respond to at least three types of conventional therapy, including artificial tears, topical or systemic antibiotics and anti-inflammatory treatments and the aforementioned heat-based therapies, over a period of at least 2 years
  5. Fitzpatrick skin type I-IV - Type V and VI skinned subjects are excluded from the study due to the high risk of pain and focal hypopigmentation
  6. Mentally fit to give informed consent

Exclusion Criteria:

  1. Fitzpatrick skin type V-VI
  2. History of eyelid scarring
  3. Infrared meibography evidence of significant acinar gland atrophy (dropout of >30%) - these patients have been shown not to benefit from heat-based therapies due to end-stage disease
  4. Pregnancy or lactation
  5. Active corneal disease such as infectious keratitis, allergic keratoconjunctivitis, pterygium, exposure keratopathy, lagophthalmos, trichiasis or dellen
  6. Current systemic intake of photosensitive medications, including tetracycline group of drugs.
  7. History of corneal abnormality or surgery within 3 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Radiofrequency treatment (RF), followed by meibomian gland expression (MGX)

Before treatment, a thermage return pad will be applied to subject's skin to help prevent electrical burns. The return pad is a rubber, non-active electrode that creates a return path for radiofrequency energy back to the thermage comfort pulse technology (CPT) system. The upper and lower lid of both eyes are marked with skin marking paper (Thermage ® Skin Marking Paper TK-3.00). Coupling fluid is then applied to the external surface of the upper and lower lids of both eyes. All subjects then receive 225 applications to each eye over the upper and lower eyelids. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.

The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction

假比较器:Sham treatment, followed by meibomian gland expression (MGX)

The training mode is used in the Thermage FLX, which simulates treatment without dissipation of radiofrequency energy. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.

Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in non-invasive keratographic tear breakup time (NIKBUT)
大体时间:From baseline to 6 months post- treatment between study groups

NIKBUT is measured in seconds and average of 3 consecutive readings is taken. Higher values mean better outcomes.

From baseline to 6 months post- treatment between study groups

次要结果测量

结果测量
措施说明
大体时间
Change in Standard Patient Evaluation of Eye Dryness (SPEED) symptom score
大体时间:From baseline to 6 months post-treatment between study groups

One number was collected per patient, with higher scores meaning worse outcomes

From baseline to 6 months post-treatment between study groups
Percentage of subjects with normal non-invasive keratographic tear breakup time (NIKBUT)
大体时间:6 months

> 10 seconds, with lower scores meaning worse

6 months
Percentage of subjects with normal SPEED
大体时间:6 months

<5, with higher scores meaning worse

6 months
Change in best corrected visual acuity
大体时间:from baseline to 6 months post-treatment

from logmar(1.0 to -0.1)

from baseline to 6 months post-treatment
Incidence of periorbital pain
大体时间:6 months

at least 3/10 and above, with higher scores meaning worse

6 months
Incidence of ocular adverse events
大体时间:6 months

evidence of uveitis, conjunctivitis, scleritis/episcleritis, new lens opacities, new cornea opacities

6 months
Incidence of non-ocular adverse events
大体时间:6 months

eyelid skin burn, eyelid redness, eyelid hyper/hypopigmentation

6 months

其他结果措施

结果测量
措施说明
大体时间
Change in cornea staining (National Eye Institute Grading System)
大体时间:from baseline to 6 months post-treatment

This serves as an objective parameter for ocular surface damage, with higher scores meaning worse

from baseline to 6 months post-treatment
Tear osmolarity
大体时间:from baseline to 6 months post-treatment

This serves as an objective parameter for ocular surface damage

from baseline to 6 months post-treatment
Change in Shirmer's I test reading
大体时间:from baseline to 6 months post-treatment

In millimetres. Readings serve as objective parameters for tear volume

from baseline to 6 months post-treatment
Tear meniscus height
大体时间:from baseline to 6 months post-treatment

In millimetres. Readings serve as objective parameters for tear volume

from baseline to 6 months post-treatment
Changes in meiboscore
大体时间:from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction

from baseline to 6 months post-treatment between study groups
Changes in meibum expressibility
大体时间:from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction, with higher scores meaning worse

from baseline to 6 months post-treatment between study groups
Changes in meibum quality
大体时间:from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction, with higher scores meaning worse

from baseline to 6 months post-treatment between study groups

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Kendrick Co SHIH、The University of Hong Kong, Grantham Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月22日

初级完成 (估计的)

2027年10月30日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2023年12月10日

首先提交符合 QC 标准的

2024年1月22日

首次发布 (实际的)

2024年1月24日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 11221686

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅